Novel nineteen compounds based on a 4-aminoquinoline scaffold were designed and synthesized as potential antiproliferative agents. The new compounds were N-substituted at the 4-position by aryl or heteroaryl (1-9), quinolin-3-yl (10), 2-methylquinolin-3-yl (11), thiazol-2-yl (12), and dapsone moieties (13, 14 and 18). Bis-compounds 15, 16 and 19 were also synthesized to assess their biological activity. All the newly synthesized comounds were tested for in vitro antipro liferative activity against the MCF-7 breast cancer cell line. Seventeen of the novel compounds showed higher ac tivi ty than the reference drug doxorubicin. The cor res pond ing 7-(trifluoromethyl)-N-(3,4,5-trimethoxyphenyl)quinolin-4-amine 1, N-(7-(trifluoromethyl)quinolin-4-yl)quino lin-3-amine (10), 2-methyl-N-(7-trifluorome-thyl)quinolin-4-yl) quinolin-3-amine (11) and N-(4-(4-aminophenylsulfonyl) phenyl)-7-chloroquinolin-4-amine (13) were almost twice to thrice as potent as doxorubicin. Biological screening of the tested compounds could offer an encouraging framework in this field that may lead to the discovery of potent anticancer agents.
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were reported to possess significant anticancer activity (11) . In view of the above mentioned findings and as a part of our research efforts to explore novel anti-proliferative heterocyclic compounds (12) (13) (14) (15) (16) (17) (18) , we have synthesized a new series of 4-aminoquinoline derivatives bearing a number of the biologically active moieties mentioned above, as analogues to compounds I and II. Anti-proliferative activity of the synthesized compounds was evaluated against the human breast cancer cell line MCF-7.
EXPERIMENTAL
Melting points (uncorrected) were determined in open capillaries on a Gallen Kemp melting point apparatus (Sanyo Gallen Kemp, UK). Precoated silica gel plates (Kieselgel 0.25 mm, 60 F254, Merck, Germany) were used for thin layer chromatography. A developing solvent system of chloroform/methanol (8:2) was used and the spots were detected by ultraviolet light. IR spectra (KBr disc) were recorded using an FT-IR spectrophotometer (Perkin Elmer, USA).
1
H NMR spectra were scanned on a NMR spectrophotometer (Bruker AXS Inc., Switzerland) operating at 500 MHz for 1 H and 125.76 MHz for 13 C. Chemical shifts are expressed in d-values (ppm) relative to TMS as an internal standard, using DMSO-d 6 as a solvent. Elemental analyses were done on a model 2400 CHNSO analyzer (Perkin Elmer, USA). All the values were within ± 0.4 % of theoretical values.
All reagents used were of AR grade. The starting materials 4,7-dichloroquinoline and 4-chloro-7-trifluoromethylquinoline were purchased from Sigma (USA) and were directly used for the preparation of target compounds. (12) . General procedure -A mixture of 4,7-dichloroquinoline or 4-chloro-7-trifluoromethylquinoline (0.01 mol) and the appropriate amine (0.01 mol) in dry (Table I) . (14) . -A mixture of 4,7-dichloroquinoline or 4-chloro-7-trifluoromethylquinoline (0.01 mol) and dapsone (2.28 g, 0.01 mol) in DMF (20 mL) was refluxed for 24 h. The obtained solid was recrystallized from dioxane to give 13 and 14, respectively (Table I) . N,N'-(4,4'-sulfonylbis(4,1-phenylene)bis(7-chloroquinolin-4-amine) (15) , N,N'-(4,4'-sulfonylbis(4,1-phenylene)bis (7-(trifluoromethyl) quinolin-4-amine) (16) . -A mixture of 4,7-dichloroquinoline or 4-chloro-7-trifluoromethylquinoline (0.02 mol) and dapsone (2.28 g, 0.01 mol) in DMF (20 mL) was refluxed for 18 h. The obtained solid was recrystallized from ethanol to give 15 and 16, respectively (Table I) . (17) . -A mixture of 4,7-dichloroquinoline (1.98 g, 0.01 mol) and ammonium thiocyanate (1.52 g, 0.01 mol) in dry acetone (20 mL) was refluxed for 1 h. The reaction mixture was cooled, poured onto ice/water and the obtained solid was recrystallized from dioxane to give 17 (Table I) . (7-chloroquinolin-4-yl) carbamimidothioic acid (18) . -A mixture of 17 (2.20 g, 0.01 mol) and dapsone (2.28 g, 0.01 mol) in DMF (20 mL) containing a catalytic amount of triethylamine was refluxed for 22 h. The obtained solid was recrystallized from acetic acid to give 18 (Table I) . (4,1-phenylene) bis(N'- (7-chloroquinolin-4-yl) carbamimido-thioic acid (19) . -A mixture of 17 (4.4 g, 0.02 mol) and dapsone (2.28 g, 0.01 mol) in DMF (20 mL) containing 3 drops of triethylamine was refluxed for 24 h. The obtained solid was recrystallized from dioxane to give 19 (Table I ).
Syntheses

Quinoline derivatives 7-(trifluoromethyl)-N-(3,4,5-trimethoxyphenyl)quinolin-4-amine (1), N-(3-methylbicyclo[3.3.1]nonan-3-yl)-7-(trifluoromethyl)quinolin-4-amine (2), 7-chloro-N-(4-morpholinophenyl)quinolin-4-amine (3), N-(4-morpholinophenyl)-7-(trifluoromethyl)quinolin-4-amine (4), 5-(7-(trifluoromethyl)quinolin-4-ylamino)pyrimidin-2,4-(1H,3H)-dione
(5), 1,3-dimeth- yl-6-(7-(trifluoromethyl)quinolin-4-ylamino)pyrimidin-2,4-(1H,3H)-dione (6), N-(benzo[d] [1,3] dio xol-5-ylmethyl)-7-chloroquinolin-4-amine (7), N-(benzo[d] [1,3] dioxol-5-ylmethyl)-7-(tri flu- oro methyl) quinolin-4-amine (8), N-(5,6-dimethyl-1,2,4-triazin-3-yl)-7-(trifuoloromethyl) quino- lin-4-amine (9), N-(7-(trifluoromethyl)quinolin-4-yl)quinolin-3-amine (10), 2-methyl-N-(7-triflu- oromethyl) quinolin-4-yl)quinolin-3-amine (11), 6-methoxy-N-(7-(trifluoromethyl) quinolin-4-yl) benzo[d]thiazol-2-amineN-(4-(4-aminophenylsulfonyl) phenyl)-7-chloroquinolin-4-amine (13) N-(4-(4-aminophenyl- sulfonyl) phenyl-7-(trifluoromethyl)quinolin-4-amine
7-Chloro-4-isothiocyanatoquinoline
N-(4-(4-aminophenylsulfonyl) phenyl)-N-
N,N-(4,4'-sulfonylbis
In vitro anti-proliferative activity
The cytotoxic activity in vitro of newly synthesized compounds was measured using the sulforhodamine B stain (SRB) assay and the method of Skehan (19) . The human breast cancer cell lines MCF7 (obtained from National Cancer Institute, Cairo, Egypt) also were maintained at 37 °C in 5 % CO 2 as subconfluent monolayers in 80 cm 3 culture flasks (Nunclon) and were subcultured once or twice weekly in Dulbecco's modification of Eagle's medium (Flow) supplemented with 5 % heat-inactivated fetal calf serum (FCS) and 1 mmol L -1 L-glutamine. During experiments, 50 µg mL -1 gentamicin was added to the culture medium. Passage levels were in the range of 5-20 according to the original receipt. Cells were harvested from exponential phase cultures by trypsinisation, counted and plated in 96-well flat bottomed microtitre plates (Greiner Labortechnik, Germany) (100 µL cell suspension containing 10 4 cells per well). Following plating and a 24-h recovery to allow cells to resume exponential growth, 100 µL culture medium or culture medium containing the drug was added to the wells. Test compounds were dissolved in DMSO as a 0.1 µmol L -1 stock solution (the final concentration of DMSO in culture medium was less than 0.1 %) and diluted with phosphate buffered saline (PBS) to form 10 µmol L -1 stock solutions. Different concentrations of each test compound (5, 12.5, 25 and 50 µmol L ) were added to the cell monolayer. Triplicate wells were prepared for each individual dose. Monolayer cells were incubated with the compound(s) for 48 h at 37 °C and in an atmosphere of 5 % CO 2 . Forty eight hours after drug addition, cells were fixed with 50 % trichloroacetic acid at 4 °C (50 µL/well) for 1 h, washed with 1 % acetic acid and stained for 30 min with 50 µL of 0.4 % (m/V) SRB dissolved in 1 % acetic acid. Excess unbound dye was removed by four washes with 1 % acetic acid and attached stain was recovered with Tris-EDTA buffer. Colour intensity was measured using an enzyme-linked immunosorbent assay ELISA reader. Optical density was read at 510 nm. The relation between the surviving fraction and drug concentration was plotted to get the survival curve for the breast cancer cell line (MCF7) after specified time (19) . The molar concentration required for 50 % inhibition of cell viability (IC 50 ) was preliminarily calculated from the constructed dose-response curve using Prism software (Graphpad, Inc., USA) and the results are given in Table III . were obtained in good yields via the reaction of 4,7-dichloroquinoline or 4-chloro-7-trifluoromethylquinoline with 3,4,5-trimethoxyaniline and 1-adamantylamine in DMF, respectively. IR spectrum of 1 revealed a characteristic band at 3390 cm -1 (NH).
1
H NMR spectrum indicated the presence of signals at 3.8 ppm, which could be assigned to 3 OCH 3 and a singlet at 9.5 ppm for the NH group.
H NMR spectrum of compound 2 exhibited signals at 1.64, 1.76 and 2.14 ppm assigned to adamantane protons (Table II) . On the other hand, when 4,7-dichloroquinoline and 4-chloro-7-trifluoromethylquinoline reacted with 4-aminomorpholine, the corresponding 4-aminomorpholinophenyl derivatives 3 and 4 were obtained, respectively. IR spectra of compounds 3 and 4 showed the presence of characteristic bands at 3189, 3360 cm -1 (NH).
H NMR spectra of 3 and 4 indicated the presence of signals at 3.1 and 3.7 ppm for 4 CH 2 of the morpholino moiety. Further, pyrimidine deri-vatives 5 and 6 were obtained in good yields via the reaction of 4-chloro-7-trifluoromethylquinoline with 5-aminouracil and 6-amino-1,3-dimethyl uracil in refluxing DMF, respectively. IR spectra exhibited the presence of an NH and 2 C=O groups.
H NMR spectrum of 5 revealed a signal at 7.6 ppm assigned to the CH of uracil and others at 11.0 and 11.4 ppm due to the 2 NHs of uracil.
1 H NMR of 6 indicated the presence of 2 CH 3 groups at 2.5 and 3.3 ppm and CH uracil at 6.5 ppm (Table II) 
H NMR spectrum of 10 revealed a singlet at 9.0 ppm for the NH group.
H NMR spectrum of 11 showed a signal at 2.4 ppm for CH 3 and another at 9.2 ppm for the NH group (Table II) . Interaction of 4-chloro-7-trifluoromethylquinoline with 6-methoxybenzothiazole afforded the corresponding benzo[d] thiazole derivative 12.
1 H NMR spectrum indicated the presence of a triplet at 1.3 ppm for the CH 3 group and a quartet at 4.0 ppm due to the CH 2 group.
On the other hand, and as depicted in Scheme 2, when 4,7-dichloroquinoline or 4-chlo ro-7-trifluoromethylquinoline reacted with dapsone in a molar ratio 1:1 in DMF, they afforded the corresponding 4-aminophenylsulfonyl derivatives 13 and 14, respectively, whereas conducting this reaction in a molar ratio 2:1, the corresponding bis-compounds 15 and 16 were obtained in good yields. IR spectra of compounds 13 and 14 showed the presence of free NH 2 bands at 6.2 ppm.
H NMR spectra of 15 and 16 revealed signals at 11.4 and 9.7 ppm for the 2 NH groups (Table II) .
Isothiocyanate derivative 17 was synthesized by treatment of compound 4,7-dichloroquinoline with ammonium thiocyanate in dry acetone for 1 h (Scheme 3). This method led to higher overall yield and shorter working time in comparison with the reported method using silver thiocyanate (19) . IR spectrum of 17 showed the characteristic band at 2072 cm -1 assigned to N=C=S. Interaction of 17 with dapsone (1:1 mol) yielded the corresponding thiourea derivative 18, whereas conducting this reaction in molar ratio 2:1 afforded the corresponding bis-compound 19. Structures of compounds 18 and 19 were supported by elemental analysis and spectral data. IR spectrum of 18 revealed the presence of a band corresponding to free NH 2 , while IR spectrum of 19 showed bands at 3440 and 3396 cm -1 for 2 NH groups.
H NMR spectrum of compound 18 exhibited signals at 2.6 ppm assigned to the SH group and 4.9 ppm attributed to the NH 2 group.
H NMR spectrum of compound 19 revealed signals at 2.7 ppm for the SH group and at 10.7 ppm due to 2 NH groups (Table II) .
In vitro anti-proliferative activity and SAR
All the newly synthesized compounds were evaluated for their in vitro cytotoxic activity against the breast cancer cell line (MCF-7) compared with that of doxorubicin. The response parameter calculated was the IC 50 value, which corresponds to the concentration required for 50 % inhibition of cell viability (Table III) . The most active derivative in this study was the 3,4,5-trimethxyphenyl4-aminoquinoline derivative (1, IC 50 = 9.38 µmol L Compd.
Compound concentration (µmol L ) displayed very high activity, being approximately double as potent as doxorubicin.
To investigate the effect of increasing lipophilicity on the biological activity of this class of compounds, the pyrimidine-2,4-dione derivative 5 and its 1,3-dimethyl analogue 6 were prepared. Cytotoxic screening results showed that the more lipophilic derivative Regarding bis-compounds, there seemed to be no priority for preparing the bis-analogues over their counterparts, since they did not demonstrate any enhancement of activity. Looking at the data for compounds 13 ) and benzothiazole derivative (12) was not active in the adopted experimental procedure.
Finally, it is noteworthy that the cells killing potency of the 7-chloro derivatives was usually better than that of their 7-trifluoromethyl. Thus, compound 7 having a chloro group at 7-position with IC 50 value 21.10 µmol L -1 was more active than compound 8 bearing trifluoromethyl moiety at the same position IC 50 value 26.20 µmol L . The presence of the chloro group at position 7 in compounds 7, 13, 15 is supposed to enhance their anticancer activity. An exception was observed by the analogous pair 3 and 4 where 7-chloro derivative 3 had lower potency (IC 50 31.50 and 23.30 µM, respectively). It is clear from the present data that the comparison of the cytotoxicity of quinoline derivatives against the breast cancer cell line (MCF7) ( Table III) has shown that the cell killing potency follows the order 1 > 10 > 11 > 13 > 7 > 5 > 9 > 17 > 18 > 15 > 4 > 6 > 14 > 16 > 2 > 8 > 3 > doxorubicin.
CONCLUSIONS
The objective of the present study was to synthesize and investigate the anti-proliferative activity of some novel derivatives based on a 4-aminoquinoline backbone carrying variable biologically active moieties, viz., trimethoxyphenyl, adamantyl, pyrimidin-2,4-dione, benzodioxole and dapsone, as well as a few bis-compounds. The anti-proliferative screening results of the new compounds against MCF-7 showed that seventeen compounds were more potent than the reference drug doxorubicin. Among them, 7-(trifluo romethyl)-N-(3,4,5-trimethoxyphenyl)quinolin-4-amine (1), N- (7-(trifluoromethyl) quinolin-4-yl)quinolin-3-amine (10), 2-methyl-N-(7-trifluoromethyl)quinolin-4-yl)quinolin-3-amine (11) and N-(4-(4-aminophenylsulfonyl)phenyl)-7-chloroquinolin-4-amine (13). 1, 10 and 11 were almost twice to thrice as potent as doxorubicin. We have inferred from the biological assessment data that this class of derivatives represents a very promising starting point for the design and synthesis of more analogues with further improved anti-proliferative activity. In vivo and toxicity studies of these compounds are under way.
